Cerus Corporation Shares Are Trading Higher After the Company Announced Its ReCePI Phase 3 Trial of INTERCEPT Blood System Met Its Primary Efficacy Endpoint
Cerus Corporation宣布其INTERCEPT血液系统的Recepi三期试验达到其主要疗效终点后,该公司股价走高
Cerus Corporation Shares Are Trading Higher After the Company Announced Its ReCePI Phase 3 Trial of INTERCEPT Blood System Met Its Primary Efficacy Endpoint
Cerus Corporation宣布其INTERCEPT血液系统的Recepi三期试验达到其主要疗效终点后,该公司股价走高
使用浏览器的分享功能,分享给你的好友吧